| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | 5-FU | CTRPv2 | pan-cancer | AAC | -0.067 | 0.05 |
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | -0.07 | 0.05 |
| mRNA | Cyclopamine | GDSC1000 | pan-cancer | AAC | -0.11 | 0.05 |
| mRNA | MS-275 | FIMM | pan-cancer | AAC | -0.26 | 0.05 |
| mRNA | AT13387 | CTRPv2 | pan-cancer | AAC | 0.087 | 0.06 |
| mRNA | Dasatinib | GDSC1000 | pan-cancer | AAC | -0.1 | 0.06 |
| mRNA | UNC0321 | CTRPv2 | pan-cancer | AAC | -0.071 | 0.06 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.073 | 0.06 |
| mRNA | erastin | CTRPv2 | pan-cancer | AAC | -0.066 | 0.06 |
| mRNA | GDC-0941 | GDSC1000 | pan-cancer | AAC | -0.064 | 0.06 |